Established · publishing since 1998Rising activity
Peptidase Inhibition and AnalysisAdenosine and Purinergic SignalingProtein Degradation and InhibitorsUbiquitin and proteasome pathwaysNanoparticle-Based Drug Delivery
Publications
102
Citations
3,289
Est. group size
—
Recurring co-author estimate
Active years
29
Publishing since 1998
In context
Among 4,953 established Medicine PIs within our index
Citations: 3,289p25 789 · p75 7,423 · cohort median 2,544
Publications / year (recent): 11.2p25 2 · p75 10.6 · cohort median 4.8
Typically publishes in teams of ~21 · 0% small-team papers (≤3 authors) · across 7 venues
Publication cadence
Publications per year over the last 10 years — averaging 11.2/year recently
Recent publications
- Abstract A015: AB801, a potent and selective clinical-stage AXL inhibitor, enhances the anti-tumor efficacy and duration of response of KRAS inhibitors
Cancer Research · 2026
- Figure S7 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
2026
- Figure S1 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
2026
- Figure S3 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
2026
- Figure S4 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
2026
- Figure S5 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
2026
- Figure S10 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
2026
- Figure S9 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
2026
- Figure S2 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
2026
- Figure S11 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
2026
- Figure S6 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
2026
- Figure S8 from Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
2026
- Discovery and Characterization of Potent, Selective, and Orally Bioavailable 7-Azaindazole AXL Receptor Tyrosine Kinase Inhibitors
Journal of Medicinal Chemistry · 2025
- Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy
Journal of Medicinal Chemistry · 2025
- Harnessing CD39 inhibition to boost antitumor immunity with extracellular ATP
The Journal of Immunology · 2025
Publishes in
- Cancer Research×17
- Journal of Medicinal Chemistry×7
- Molecular Cancer Therapeutics×5
- Neoplasia×4
- Regular and Young Investigator Award Abstracts×3
Similar researchers
By research-topic overlap
- Renqi Xu
Medicine · University of Michigan
- Matthew S. Stratton
Medicine · The Ohio State University
- Özlem Doǧan Ekici
Medicine · The Ohio State University
- John Takyi‐Williams
Medicine · University of Michigan
- Yi-Hsun Ho
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile